Markets

Ultragenyx drug fails phase 3 trial for Angelman syndrome

2 sources ·2 articles ·1h ago

2 outlets - including Statnews and Investing - are covering this story. Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.

Covered by 2 outlets

Statnews 1 Investing 1

All coverage · 2 articles

STAT News ·1h ago

STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.

Investing.com UK ·1h ago

Ultragenyx drug fails phase 3 trial for Angelman syndrome

STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial →

Ultragenyx drug fails phase 3 trial for Angelman syndrome →

STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Ultragenyx drug fails phase 3 trial for Angelman syndrome